Japan Core Inflation Seen Rising in June, Strengthening BOJ Rate Hike Outlook 
Brazil Weighs IP Curbs, Patent Suspensions After New U.S. Tariffs 
US Stock Futures Hold Steady as Tesla, Alphabet Earnings and Iran Conflict Dominate Market Focus 
Oil Prices Hold Steady as U.S.-Iran Conflict and Houthi Blockade Keep Markets on Edge 
Deutsche Bank Says Fed Balance Sheet Cuts Could Weaken US Dollar Instead of Boosting It 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
GameStop Raises eBay Stake to 9.8% as Ryan Cohen Pushes $56 Billion Takeover Bid 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
Asian Currencies Hold Steady as Fed Outlook Offsets Middle East Tensions 
KKR, AEW Seek China Property Sales as Commercial Real Estate Slump Deepens 
European Earnings Season Gains Strength as Barclays Sees Broader Profit Recovery 
Seven & i Eyes Żabka Stake in Major European Expansion Push 
Why Maruti Suzuki Is Losing Market Share in India as SUVs and Premium Features Gain Popularity 
Lockheed Martin Unveils Lower-Cost Patriot ACE Interceptor to Meet Rising Air Defense Demand 
South Korea’s Coupang Fine Sparks U.S. Criticism, Raising Concerns Over Bilateral Ties 
TSMC Sees Multi-Year AI Chip Demand as Arizona Expansion Reaches $265 Billion 
SpaceX Eyes Pentagon AI Deal as Cloud Pricing Strategy Pressures CoreWeave 
Novartis unveiled its restructuring plans on Tuesday, June 28, but the program may also lead to job cuts, and around 8,000 employees are set to be affected. The Swiss -American multinational pharmaceutical company headquartered in Basel, Switzerland and Cambridge, Massachusetts, said that the reduction of its workforce will give them a savings of up to $1 billion by the year 2024.
As per Reuters, Novartis actually announced its restructuring program weeks before, and it has reaffirmed that it is set to let go of around 7.4% of its total workforce globally. The firm said that up to 1,400 workers based in Switzerland are also affected.
Previously, the projected job cuts were revealed by Novartis' chief executive officer, Vas Narasimhan. He explained back in April that it will be a "single digit thousands," and the company is doing this as part of a reorganization to save money.
The company shared through an email message that since the announcement, it has made good progress in the implementation of its new organizational structure. Under the program, Novartis has merged its pharmaceuticals and oncology business divisions. On the downside, this move entails the termination of some job roles throughout the organization.
"This restructuring could potentially impact 1,400 positions based in Switzerland, out of around 8,000 positions impacted globally," the company was quoted as saying in the email. The termination of workers was also confirmed by a local Swiss paper TagesAnzeiger. Currently, Novartis employs 108,000 staff worldwide, and 11,600 of them are based in Switzerland.
The restructuring comes as the company's chief Narasim is trying to bolster his efficiency credentials since Novartis is receiving huge cash windfalls that include a $20.7 billion last year from the sale of its 33% stake to its rival company, Roche.
Meanwhile, Bloomberg reported that the latest layoffs will fall heavily on the company's operations in Switzerland since it will be eliminating more than a thousand workers. The company also clarified that it has initiated consultations with employees at its HQ prior to the cutbacks.
"The new structure will be both leaner and simpler and as such the company intends to eliminate roles across the organization, subject to local information and consultation requirements," Novartis explained.
